In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae

ABI-1648 (rifalazil) is a semisynthetic rifamycin with potent bactericidal activity against intracellular respiratory bacteria, including Mycobacterium tuberculosis, and a long half-life (∼60 h) and thus can be administered once weekly. We therefore tested the in vitro activities of ABI-1648, its de...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Roblin, Patricia M., Reznik, Tamara, Kutlin, Andrei, Hammerschlag, Margaret R.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2003
Soggetti:	Susceptibility
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC149300/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12604555/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.3.1135-1136.2003
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!